Medicine

G. Brown, J.J. Albers, L.D. Fisher, S.M. Schaefer, et al., "Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipopro-tein B," New England Journal of Medicine, 323:1289-98, 1990. Greg Brown (University of Washington Medical Center, Seattle): "We have long known that cholesterol-loaded arteries in experimental animals will improve under conditions of low blood cholesterol; and clinical studies have been completed showing that red

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

G. Brown, J.J. Albers, L.D. Fisher, S.M. Schaefer, et al., "Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipopro-tein B," New England Journal of Medicine, 323:1289-98, 1990.

Greg Brown (University of Washington Medical Center, Seattle): "We have long known that cholesterol-loaded arteries in experimental animals will improve under conditions of low blood cholesterol; and clinical studies have been completed showing that reduction in cholesterol will result in an improvement in heart disease risk. Why, then, has it taken so long to show that cholesterol-lowering therapy can improve the diseased coronary arteries in such patients?

"First, an arterial disease measurement technique, such as the computer-assisted method developed in 1975 in our laboratory, was needed for objective analysis of atherosclerosis progression and regression. Second, more powerful diet and double drug combinations were found, which dramatically lowered LDL- and raised HDL-cholesterol. Third, we ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies